Part 2: Size exclusion chromatography with light scattering for biopharmaceuticals
September 29, 2025, at 16:00 BST / 17:00 CEST / 11:00 EDT / 08:00 PDT
Biopharmaceuticals based on monoclonal antibodies, lipid nanoparticle-encapsulated mRNA, and transgene-carrying viral vectors, are significantly larger than traditional small-molecule drugs. This size difference requires specialized analytical tools. Size-exclusion chromatography (SEC) is particularly effective for studying proteins and has recently been adapted to analyze complex macromolecular assemblies like mRNA and DNA.
Join us for this exciting two-part webinar series where Dr. Jelle De Vos from RIC group and Dr. Sonja Schneider from Agilent Technologies will discuss how SEC is evolving to meet the demands of modern biopharma. In Part 2, our experts will share real-world application examples of SEC with light scattering detection, highlighting how this powerful combination is transforming the analysis of complex biopharmaceuticals.
Key learning objectives of Part 2:
- Understand the practical application of SEC for the characterization of:
- monoclonal antibodies
- mRNA-lipid nanoparticle formulations
- adeno-associated viruses (AAVs)
- virus-like particles (VLPs)
Who should attend?
- Scientists and researchers in biotherapeutics R&D using SEC/light scattering.
- Lab and quality leaders, including lab managers, directors, and QA/QC professionals in biopharma production.
Want to go back and watch Part 1?
Click here to register for Part 1, and hear the fundamentals of SEC and discover how coupling it with light scattering detection can advance the characterization and development of biopharmaceuticals.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Dr. Jelle De Vos currently works at the RIC group as an expert in developing chromatography methodologies for analyzing complex biopharmaceutical samples. His work focuses on pushing the boundaries of modern separation science, and he has published over 40 articles on advancing the limits of ultra high-performance liquid chromatography and developing microfluidic technology.
Dr. Sonja Schneider is an Application Scientist at Agilent Technologies in Waldbronn, Germany, who has published numerous application notes on the analysis of biopharmaceuticals. After obtaining her PhD in proteomics in 2011, she started as an Application Scientist for Bioanalytics and has been working various kinds of critical quality attributes of monoclonal antibodies, mRNA, and LNPs.
Moderator
